1. Home
  2. WNS vs IBRX Comparison

WNS vs IBRX Comparison

Compare WNS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WNS
  • IBRX
  • Stock Information
  • Founded
  • WNS 1996
  • IBRX 2014
  • Country
  • WNS India
  • IBRX United States
  • Employees
  • WNS N/A
  • IBRX N/A
  • Industry
  • WNS Business Services
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WNS Consumer Discretionary
  • IBRX Health Care
  • Exchange
  • WNS Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • WNS 2.8B
  • IBRX 2.4B
  • IPO Year
  • WNS N/A
  • IBRX N/A
  • Fundamental
  • Price
  • WNS $61.09
  • IBRX $2.58
  • Analyst Decision
  • WNS Buy
  • IBRX Strong Buy
  • Analyst Count
  • WNS 8
  • IBRX 5
  • Target Price
  • WNS $63.00
  • IBRX $11.35
  • AVG Volume (30 Days)
  • WNS 856.8K
  • IBRX 7.9M
  • Earning Date
  • WNS 04-24-2025
  • IBRX 05-08-2025
  • Dividend Yield
  • WNS N/A
  • IBRX N/A
  • EPS Growth
  • WNS 31.09
  • IBRX N/A
  • EPS
  • WNS 3.71
  • IBRX N/A
  • Revenue
  • WNS $1,314,900,000.00
  • IBRX $14,745,000.00
  • Revenue This Year
  • WNS N/A
  • IBRX $621.53
  • Revenue Next Year
  • WNS $8.06
  • IBRX $163.57
  • P/E Ratio
  • WNS $17.49
  • IBRX N/A
  • Revenue Growth
  • WNS N/A
  • IBRX 2270.58
  • 52 Week Low
  • WNS $39.85
  • IBRX $2.28
  • 52 Week High
  • WNS $72.11
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • WNS 41.88
  • IBRX 44.86
  • Support Level
  • WNS $61.66
  • IBRX $2.35
  • Resistance Level
  • WNS $66.50
  • IBRX $2.87
  • Average True Range (ATR)
  • WNS 4.05
  • IBRX 0.25
  • MACD
  • WNS -0.55
  • IBRX 0.01
  • Stochastic Oscillator
  • WNS 10.55
  • IBRX 33.58

About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)

WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: